Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

34.26USD
23 Sep 2016
Change (% chg)

$0.11 (+0.32%)
Prev Close
$34.15
Open
$34.16
Day's High
$34.37
Day's Low
$34.01
Volume
12,937,101
Avg. Vol
21,490,570
52-wk High
$37.39
52-wk Low
$28.25

PFE

Chart for PFE

About

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor,... (more)

Overall

Beta: 0.86
Market Cap(Mil.): $207,809.30
Shares Outstanding(Mil.): 6,065.65
Dividend: 0.30
Yield (%): 3.50

Financials

  PFE Industry Sector
P/E (TTM): 30.41 36.61 36.60
EPS (TTM): 1.13 -- --
ROI: 5.11 14.46 13.91
ROE: 10.78 15.26 14.82

BRIEF-Pfizer announces expiration of Hart-Scott-Rodino waiting period for acquisition of medivation

* Pfizer announces expiration of Hart-Scott-Rodino waiting period for proposed acquisition of medivation

Sep 23 2016

BRIEF-Pfizer declares 30-cent fourth-quarter 2016 dividend

* Pfizer declares 30-cent fourth-quarter 2016 dividend Source text for Eikon: Further company coverage:

Sep 22 2016

REFILE-DEALTALK-Allergan pays top dollar for 'stepping stones' from neurology to dermatology

Sept 20 Allergan Plc CEO Brent Saunders calls them "stepping stones" - small, bolt-on acquisitions, as opposed to the mega-deals common in the drug industry. And they're expected to boost dealmaking in sectors ranging from neurology to skin care.

Sep 20 2016

Allergan pays top dollar for 'stepping stones' from neurology to dermatology

Allergan Plc CEO Brent Saunders calls them "stepping stones" - small, bolt-on acquisitions, as opposed to the mega-deals common in the drug industry. And they're expected to boost dealmaking in sectors ranging from neurology to skin care.

Sep 20 2016

BRIEF-Pfizer reports positive top-line results from reflections B537-02 study for PF-06438179

* Results confirm similar efficacy of PF-06438179 (Infliximab-pfizer) to Remicade(REG) (Infliximab), in combination with Methotrexate

Sep 16 2016

EMA panel recommends nod for Pfizer's breast cancer drug

U.S. drugmaker Pfizer Inc's breast cancer drug, Ibrance, should be given marketing approval, an advisory committee at the European Medicines Agency recommended.

Sep 16 2016

UPDATE 1-EMA panel recommends nod for Pfizer's breast cancer drug

Sept 16 U.S. drugmaker Pfizer Inc's breast cancer drug, Ibrance, should be given marketing approval, an advisory committee at the European Medicines Agency recommended.

Sep 16 2016

EMA advisory panel recommends nod for Pfizer's breast cancer drug

Sept 16 U.S. drugmaker Pfizer Inc's breast cancer drug, Ibrance, should be given marketing approval, an advisory committee at the European Medicines Agency recommended.

Sep 16 2016

BRIEF-Oncoimmune announces option and license agreement with Pfizer Inc

* Oncoimmune announces option and license agreement with Pfizer Inc.

Sep 15 2016

BRIEF-Merck, Pfizer say investigational Ertugliflozin met primary endpoint

* Merck and pfizer announce investigational Ertugliflozin met primary endpoint of A1C reduction when added to Sitagliptin and Metformin in people with type 2 diabetes

Sep 15 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $118.81 -0.65
Novartis AG (NOVN.S) CHF79.15 -0.10
Merck & Co., Inc. (MRK.N) $62.96 -0.06
Roche Holding Ltd. (ROG.S) CHF245.50 +0.40
Roche Holding Ltd. (RO.S) CHF245.60 -0.10
Abbott Laboratories (ABT.N) $42.19 -0.03
Bayer AG (BAYGn.DE) €91.48 -0.74
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €68.45 -0.48
AstraZeneca plc (AZN.L) 5,170.00p +13.00

Earnings vs. Estimates